Association of Chemerin Plasma Concentration With Risk of Colorectal Cancer

Eichelmann, Fabian; Schulze, Matthias B.; Wittenbecher, Clemens; Menzel, Juliane; Weikert, Cornelia; Giuseppe, Romina di; Biemann, Ronald; Isermann, Berend; Fritsche, Andreas; Boeing, Heiner; Aleksandrova, Krasimira

doi:10.1001/jamanetworkopen.2019.0896

Cited by 28 publications

(24 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies described a role of chemerin in CRC pathophysiology and diagnosis [7,8,9]. Chemerin is a chemoattractant protein most abundant in adipocytes and hepatocytes [10].…”

Section: Introductionmentioning

confidence: 99%

“…High plasma chemerin predicted a greater risk of CRC. Notably, this association was still significant when CRC risk factors such as age, body mass index and dietary habits were considered [8]. A second study detected higher chemerin in patients with CRC compared to healthy controls.…”

Section: Introductionmentioning

confidence: 99%

“…Of note, circulating chemerin was positively associated with all of the components of the metabolic syndrome [10,24,25]. Therefore, chemerin´s association with CRC may in part stem from the relationship between CRC and features of the metabolic syndrome [7,8,10,14,24,25]. Metabolic diseases also contribute to HCC development [22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma

Feder

Kandulski

Schacherer

et al. 2019

IJMS

View full text Add to dashboard Cite

The chemoattractant adipokine chemerin is related to the metabolic syndrome, which is a risk factor for different cancers. Recent studies provide evidence that chemerin is an important molecule in colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Serum chemerin is high in CRC patients and low in HCC patients and may serve as a differential diagnostic marker for HCC and liver metastases from CRC. To this end, serum chemerin was measured in 36 patients with CRC metastases, 32 patients with HCC and 49 non-tumor patients by ELISA. Chemerin serum protein levels were, however, similar in the three cohorts. Serum chemerin was higher in hypertensive than normotensive tumor patients but not controls. Cancer patients with hypercholesterolemia or hyperuricemia also had increased serum chemerin. When patients with these comorbidities were excluded from the calculation, chemerin was higher in CRC than HCC patients but did not differ from controls. Chemerin did not correlate with the tumor markers carcinoembryonic antigen, carbohydrate antigen 19-9 and alpha-fetoprotein in both cohorts and was not changed with tumor-node-metastasis stage in HCC. Chemerin was not associated with hepatic fat, liver inflammation and fibrosis. To conclude, systemic chemerin did not discriminate between CRC metastases and HCC. Comorbidities among tumor patients were linked with elevated systemic chemerin.

show abstract

“…Recent studies described a role of chemerin in CRC pathophysiology and diagnosis [7,8,9]. Chemerin is a chemoattractant protein most abundant in adipocytes and hepatocytes [10].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma

Feder

Kandulski

Schacherer

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Finally, chemerin is thought to exert chemotactic, adipogenic, and angiogenic functions. Higher chemerin levels are associated with CRC risks [278,279] A schematic summarizing colon disease-associated adipokine alterations and the basis is provided in Figure 2.…”

Section: Other Adipokinesmentioning

confidence: 99%

Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression

Chang

Yang

2020

IJMS

View full text Add to dashboard Cite

Adipose tissue is a highly dynamic endocrine tissue and constitutes a central node in the interorgan crosstalk network through adipokines, which cause pleiotropic effects, including the modulation of angiogenesis, metabolism, and inflammation. Specifically, digestive cancers grow anatomically near adipose tissue. During their interaction with cancer cells, adipocytes are reprogrammed into cancer-associated adipocytes and secrete adipokines to affect tumor cells. Moreover, the liver is the central metabolic hub. Adipose tissue and the liver cooperatively regulate whole-body energy homeostasis via adipokines. Obesity, the excessive accumulation of adipose tissue due to hyperplasia and hypertrophy, is currently considered a global epidemic and is related to low-grade systemic inflammation characterized by altered adipokine regulation. Obesity-related digestive diseases, including gastroesophageal reflux disease, Barrett’s esophagus, esophageal cancer, colon polyps and cancer, non-alcoholic fatty liver disease, viral hepatitis-related diseases, cholelithiasis, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, and diabetes, might cause specific alterations in adipokine profiles. These patterns and associated bases potentially contribute to the identification of prognostic biomarkers and therapeutic approaches for the associated digestive diseases. This review highlights important findings about altered adipokine profiles relevant to digestive diseases, including hepatic, pancreatic, gastrointestinal, and biliary tract diseases, with a perspective on clinical implications and mechanistic explorations.

show abstract

“…The National Comprehensive Cancer Network Guideline recommends chemotherapy combined with CET or BV as a first-line treatment for metastatic colorectal cancer (Eichelmann et al, 2019). Since the approval of targeted drugs in the early 21st century, a number of large clinical studies have shown that the overall survival (OS) of patients with metastatic colorectal cancer has increased by nearly one year compared with chemotherapy alone (Modest et al, 2015;Venook et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Liu

Jia

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Huangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC). Objective: To evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC. Methods: We performed a randomized, controlled, and double-blind trial and recruited patients with mCRC who were planned to undergo chemotherapy combined with CET or BV. The treatment group was treated with Huangci Granule, while the control group was treated with placebo. Continuous treatment until disease progression, death, intolerable toxicity or up to 6 months. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was quality of life and safety. Result: 320 patients were randomly assigned to receive treatment, including 200 first-line patients and 120 second-line patients. In the first-line treatment, the median PFS was 9.59 months (95% CI, 6.94-13.25) vs 6.89 months (95% CI, 4.99-9.52) in treatment group and control group (HR, 0.69; 95% CI, 0.50-0.97; P = 0.027). Chinese medicine was an independent factor affecting the PFS. In the second-line treatment, the median PFS was 6.51 months (95% CI, 4.49-9.44) vs 4.53 months (95% CI, 3.12-6.57) in the treatment group and control group (HR, 0.65; 95% CI, 0.45-0.95; P = 0.020). Compared with the control group, "role function," "social function," "fatigue," and "appetite loss" were

show abstract

Association of Chemerin Plasma Concentration With Risk of Colorectal Cancer

Cited by 28 publications

References 58 publications

Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma

Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma

Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Contact Info

Product

Resources

About